Marbocyl P 20 mg containing 20 mg marbofloxacin. For use in dogs and cats.
Marbocyl is indicated for the treatment of skin and soft tissue infections (skin fold pyoderma, impetigo, folliculitis, furunculosis, cellulitis), for the treatment of urinary tract infections associated or not with prostatitis and respiratory tract infections, caused by susceptible strains of organisms.
In Cats (Marbocyl P 5mg Tablet only)
Marbocyl is indicated for the treatment of skin and soft tissue infections (wounds, abscesses, phlegmons) and upper respiratory tract infections caused by susceptible strains of organisms.
The recommended dose rate is 2 mg/kg per day in a single daily administration.
In dogs for the treatment of skin and soft tissue infections, treatment duration is at least five days. Depending on the course of the disease it may be extended up to 40 days. In urinary tract infections, treatment duration is at least 10 days. Depending on the course of the disease it may be extended up to 28 days. In respiratory infections, treatment duration is at least 7 days and, depending on the course of the disease, may be extended up to 21 days.
In cats for the treatment of skin and soft tissue infections, treatment duration is 3–5 days. For upper respiratory infections, treatment duration is 5 days.
Contra-indications, warnings, etc
Marbofloxacin should not be used in dogs aged less than 12 months or less than 18 months for exceptionally large breeds of dogs, such as Great Danes, Briard, Bernese, Bouvier and Mastiffs with a longer growth period. Not recommended for use in cats aged less than 16 weeks.
Not suitable for infections resulting from strict anaerobes, yeast or fungi.
The fluoroquinolones have been shown to induce erosion of articular cartilage in juvenile dogs and care should be taken to dose accurately, especially in young animals.
The fluoroquinolones are known for their potential neurological side effects; cautious use is recommended in dogs and cats diagnosed as suffering from epilepsy.
A low urinary pH could have an inhibitory effect on the activity of Marbofloxacin.
Mild side effects such as vomiting, softening of faeces, modification of thirst or transient increase in activity may occasionally occur. These signs cease spontaneously after treatment and do not necessitate cessation of the treatment.
At the therapeutic recommended dosage no severe side effects are to be expected. In particular no lesions of the articular joints were encountered in clinical studies at the recommended dose rate.
Studies in pregnant rats and rabbits showed no side effects on pregnancy. However, no specific studies have been carried out in pregnant cats and dogs.
Fluoroquinolones are known to interact with orally administered cations (Aluminium, Calcium, Magnesium, Iron.) In such cases, the bioavailability may be reduced.
Overdosage may cause acute signs in the form of neurological disorders which should be treated symptomatically.
Do not use Marbocyl P 20mg or Marbocyl P 80mg tablets in cats. For the treatment of this species the Marbocyl P 5mg tablet is available.
People with known hypersensitivity to fluoroquinolones should avoid using this product. In case of accidental ingestion seek medical attention and show product label and/or package leaflet to the doctor. Wear gloves when handling or dividing tablets. Wash hands after use.
This item can be dispensed in any quantity. Enter the number your prescription permits in to the Quantity box